Data / Form D filings / Comanche Biopharma Corp.
Comanche Biopharma Corp.: Form D filings
Comanche Biopharma Corp., a pharmaceuticals company in Concord, MA, filed 2 Form D notices with the SEC between 2023 and 2024. The latest, on January 17, 2024, reports $37.5 million sold of a $75 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 50 Beharrell Street, #50-B, Concord, MA, 01742
- Phone
- (617) 206-3776
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1873062
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 17, 2024 | New notice | $75,000,000 | $37,500,000 | $37,500,000 | 7 | Dec 14, 2023 | sec.gov |
| May 12, 2023 | New notice | $36,100,007 | $36,100,007 | 7 | Jun 28, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ann Scott Taylor | Director | |
| Brendan Scott Bulik-Sullivan | Director | |
| Muzammil Scott Mansuri | Director | |
| Allison Scott August | Executive Officer | |
| Paul Scott Antinori | Executive Officer | |
| Allyson Scott Felix | Director | |
| David Scott Grayzel | Director | |
| Thomas Scott Johnson | Executive Officer, Director | |
| Scott Scott Gottlieb | Director | |
| Ketan Scott Patel | Director | |
| Michael Scott Young | Executive Officer |
Other pharmaceuticals companies in Massachusetts that filed recently
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Jan 15, 2024 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Comanche Biopharma Corp. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.